← Browse by Condition
Medical Condition

polycythemia vera

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for polycythemia vera sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — polycythemia vera Clinical Trials

How many clinical trials are currently recruiting for polycythemia vera?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for polycythemia vera, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for polycythemia vera?
polycythemia vera research spans Phase 1 (1 trial), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a polycythemia vera clinical trial?
Eligibility criteria for polycythemia vera trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
3
Top Sponsors
Institute of Hematology & Blood Diseases Hospital, China 1 trial
Zhenya Hong 1 trial
University of California, Irvine 1 trial
University of Washington 1 trial

Recruiting Clinical Trials

NCT05870475 Phase 2
Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Enrollment
94 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT06734637
Recruiting

Efficacy and Safety of Peginterferon in ET and PV.

Enrollment
40 pts
Location
China
Sponsor
Zhenya Hong
View Trial →
NCT05123365 Phase 1, Phase 2
Recruiting

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Enrollment
27 pts
Location
United States
Sponsor
University of California, Irvi...
View Trial →
NCT04282187 Phase 2
Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Enrollment
25 pts
Location
United States
Sponsor
University of Washington
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology